Blog
RSS FeedPosted by Michael Wonder on 10 Dec 2022
Pfizer and BioNTech receive US FDA fast track designation for single dose mRNA based vaccine candidate against COVID-19 and influenza
9 December 2022 - Pfizer and BioNTech today announced the companies have received fast track designation from the US FDA ...
Posted by Michael Wonder on 07 Sep 2022
First combination COVID-19 and influenza self-tests approved for Australia
7 September 2022 - The TGA has approved the first two nasal combination self-tests (for use at home) that detect ...
Posted by Michael Wonder on 17 May 2022
FDA authorises first COVID-19 test available without a prescription that also detects influenza and RSV
16 May 2022 - The EUA authorises at home sample collection with testing performed in a laboratory. ...
Posted by Michael Wonder on 29 Mar 2022
Seqirus receives Health Canada approval for expanded age indication of its cell-based quadrivalent influenza vaccine for people as young as six months
28 March 2022 - Seqirus announced today that it has received Health Canada approval of Flucelvax Quad (influenza vaccine), its cell-based ...
Posted by Michael Wonder on 28 Mar 2022
2022 seasonal influenza vaccines
25 March 2022 - The Australian Influenza Vaccine Committee has reviewed data related to epidemiology, antigenic and genetic characteristics of recent ...
Posted by Michael Wonder on 29 Jun 2021
Update of EU recommendations for 2021–2022 seasonal flu vaccine composition
28 June 2021 - EMA has issued an update of the EU recommendations for the influenza virus strains that vaccine ...
Posted by Michael Wonder on 24 Mar 2021
Seqirus ready to reinforce Canada's influenza pandemic preparedness plans
23 March 2021 - Health Canada's approval of Foclivia (an adjuvanted, egg-based A strain H5N1 pandemic influenza vaccine) meets key requirement ...
Posted by Michael Wonder on 24 Mar 2021
Super flu vaccine gets the go-ahead
24 March 2021 - A new type of cell-based influenza vaccine is available this winter that promises to be significantly ...
Posted by Michael Wonder on 22 Sep 2020
CHMP recommends approval of Supemtek (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older
22 September 2020 - Positive opinion based on clinical data demonstrating safety and efficacy of Supemtek for adults aged 18 and ...
Posted by Michael Wonder on 09 Sep 2020
TGA approves yet another flu vaccine
9 September 2020 - As its brand name suggests, Flucelvax Quad is a new quadrivalent influenza vaccine. ...
Posted by Michael Wonder on 09 Jun 2020
First adjuvanted quadrivalent influenza vaccine by Seqirus receives EU approval
8 June 2020 - The European Commission has today given regulatory approval for the first adjuvanted quadrivalent influenza vaccine to become ...
Posted by Michael Wonder on 08 May 2020
Influenza vaccines released for 2020 season
8 May 2020 - Six influenza vaccines are available in Australia in 2020. All of these vaccines are quadrivalent, which ...
Posted by Michael Wonder on 16 Mar 2020
2020 seasonal influenza vaccines
13 March 2020 - The Australian Influenza Vaccine Committee has reviewed data related to epidemiology, antigenic and genetic characteristics of ...
Posted by Michael Wonder on 04 Feb 2020
Seqirus announces U.S. FDA approval of its first-ever adjuvanted, cell-based pandemic influenza A (H5N1) vaccine
3 February 2020 - Seqirus, a global leader in influenza prevention and pandemic response, today announced that the U.S. FDA ...
Posted by Michael Wonder on 16 Jan 2020
Novavax granted fast track designation for NanoFlu in older adults
15 January 2020 - Novavax today announced that the U.S. FDA has granted fast track designation for NanoFlu, its recombinant quadrivalent ...